Drugs / IKT-001PRO FREE BASE
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06643143 | Jun 2025 → Jun 2027 | pulmonary arterial hypertension | Inhibikase Therapeutics | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05623774 Comparator | Dec 2022 → Jun 2024 | chronic myeloid leukemia | Inhibikase Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IKT-001PRO FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5316157 ↗ |
| Known as | IkT001-Pro | “up to 16 subjects will receive IkT001-Pro and up to 16 subjects will receive 400mg of imatinib mesylate” NCT05623774 ↗ |
| Modality | Small molecule | — CHEMBL5316157 ↗ |